Gilead Sciences, Inc. with ticker code (GILD) now have 25 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between $117.00 and $67.00 calculating the mean target share price we have $81.21. (at the time of writing). Given that the stocks previous close was at $62.79 and the analysts are correct then we can expect a percentage increase in value of 29.3%. Also worth taking note is the 50 day moving average now sits at $66.19 and the 200 moving average now moves to $74.33. The total market capitalization for the company now stands at 80.07B. The stock price for the company is currently $64.27 USD
The potential market cap would be $103,560,237,101 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 178.53, revenue per share of $22.00 and a 10.5% return on assets.
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy, Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir) is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV) (Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors targeting PARP1 for oncology and MK2 for inflammatory diseases.
